| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |